FAQ

Liter Per Hour Per Square Meter

Known as: (l/h)/m2, L/h/m2, Liters per Hour per Square Meter 
A unit expressed as one liter of volume per unit of time equal to one hour per square meter of area.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1988-2018
012319882018

Related topics

Related topics

1 relation
Clinical Data Interchange Standards Consortium Terminology

Related mentions per year

Related mentions per year

1988-2018
19801990200020102020
Liter Per Hour Per Square Meter
Clinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial
Doxorubicin is a key component in many pediatric oncology treatment regimens; still pharmacology data on which current dosing… (More)
Is this relevant?
2006
2006
PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
BACKGROUND The aim of this study was to determine the pharmacokinetics (PKs) of a 175-mg fixed dose of paclitaxel (PAC) after a 1… (More)
Is this relevant?
2004
2004
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study
Liposomal encapsulation of doxorubicin is designed to increase safety and tolerability by decreasing cardiac and gastrointestinal… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 5
  • table 2
Is this relevant?
2001
2001
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
BACKGROUND Previous work demonstrated that 5-fluorouracil (5-FU) metabolism is a critical factor for treatment tolerability. In… (More)
Is this relevant?
2001
2001
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
OBJECTIVES This trial was performed to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and… (More)
Is this relevant?
2000
2000
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
SAM486A (previously termed CGP 48664), a potent inhibitor of S-adenosylmethionine decarboxylase, is under clinical development… (More)
Is this relevant?
2000
2000
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
The aim of this study was to investigate the clinical pharmacokinetics of 5-fluorouracil (5-FU) and its major metabolite 5-fluoro… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
1991
1991
Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases.
Phase I and pharmacokinetic studies were performed in order to evaluate the maximum tolerated dose and the efficiency of 120 h… (More)
Is this relevant?
1991
1991
Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Thirty two patients with refractory or recurrent acute leukemia or blast crisis of chronic myelocytic leukemia were treated with… (More)
Is this relevant?
1988
1988
Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma.
The disposition of cyclophosphamide was determined in 12 women with ovarian carcinoma receiving cyclophosphamide 500 mg/m2… (More)
Is this relevant?